Dedication to biosimilars
We’ve been investing significantly in advancing biotechnology for almost four decades, and will continue to do so with biosimilars.
Our four-decade investment in biologics demonstrates a depth of experience in researching, developing, and manufacturing medicines, and we’re applying that experience to develop biosimilars across multiple therapeutic areas.
Substantial expertise and infrastructure
Amgen has expertise, global infrastructure, and capital to maintain supply reliability for the long-term across our entire portfolio of biologics, so you can be sure our medicines will be there for every Amgen patient who needs them, every time.2
Delivering high-quality, reliably supplied innovator biologic and biosimilar medicines is made possible with Amgen’s global infrastructure that is strengthened through the implementation of next-generation manufacturing.3
Amgen has a longstanding commitment to innovation in biotechnology. We strive to improve our standards of excellence, and we hope to lead the way in shaping the future of biologic manufacturing. These new standards involve incorporating new technologies, processes, and equipment that help make the production process more efficient, consistent, versatile, and demand-driven.
References: 1. Amgen Fact Sheet. Accessed August 21, 2018. Available at: https://www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx. 2. Amgen. Unlocking the Potential of Biology for Patients. www.amgen.com/~/media/amgen/full.www-amgen-com/downloads/amgen_corporate_brochure.ashx. Published August 2016. Accessed August 21, 2018. 3. Amgen Corporate Brochure: The Amgen Difference. https://www.theamgendifference.com/assets/doc/theamgendifference.pdf. Accessed August 21, 2018.
Next: Impact of